Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 8, 2010, Pages 1506-1512

  Lau, Keith K ^a   Tancredi, Daniel J ^b   Perez, Richard V ^c   Butani, Lavjay ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; PREVALENCE; SCHOOL CHILD; STEROID THERAPY; TREATMENT OUTCOME;

ADOLESCENT; BIOLOGICAL MARKERS; CALIFORNIA; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PRAVASTATIN; RETROSPECTIVE STUDIES; STEROIDS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77955744553     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08431109     Document Type: Article

References (40)

1. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS: Hyperlipidemia in renal transplant recipients: Natural history and response to treatment. Medicine (Baltimore) 73: 215-223, 1994
2. Kobashigawa JA, Kasiske BL: Hyperlipidemia in solid organ transplantation. Transplantation 63: 331-338, 1997
3. Andany MA, Kasiske BL: Dyslipidemia and its management after renal transplantation. J Nephrol 14: S81-S88, 2001
4. Pirsch JD, D'Alessandro AM, Sollinger HW, Knechtle SJ, Reed A, Kalayoglu M, Belzer FO: Hyperlipidemia and transplantation: Etiologic factors and therapy. J Am Soc Nephrol 2: S238-S242, 1992
5. Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM: A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 18: 274-280, 2004
6. Marubayashi S, Ohdan H, Tashiro H, Tokita D, Onoe T, Hayamizu K, Asahara T, Doi S, Okumoto S, Tanji C, Kawai T, Taniguchi Y, Fukuda Y, Dohi K: Studies on post-transplant dyslipidemia in kidney transplant patients. Hiroshima J Med Sci 54: 39-45, 2005
7. Kasiske BL: Cardiovascular disease after renal transplantation. Semin Nephrol 20: 176-187, 2000
8. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI, Danovitch GM: The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 61: 1469-1474, 1996
9. Butani L, Pai MV, Makker SP: Pilot study describing the use of pravastatin in pediatric renal transplant recipients. Pediatr Transplant 7: 179-184, 2003
10. Butani L: Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Pediatr Transplant 9: 746-753, 2005
11. Centers for Disease Control and Prevention: A SAS Program for the CDC Growth Charts. Available at http://www.cdc.gov/nccdphp/dnpa/growthcharts/ resources/sas.htm. Accessed November 20, 2009
12. US Department of Health and Human Services: Lipids Research Clinics Program. In: The Lipid Research Clinics Population Studies Data Book, Vol. 1. The Prevalence Study. Bethesda, MD, National Institutes of Health, pp 1527, 1980
13. Kinosian B, Glick H, Garland G: Cholesterol and coronary heart disease: Predicting risks by levels and ratios. Ann Intern Med 121: 641-647, 1994
14. Ballantyne CM, Hoogeveen RC: Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J 146: 227-233, 2003
15. Frontini MG, Srinivasan SR, Xu J, Tang R, Bond MG, Berenson GS: Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study. Pediatrics 121: 924-929, 2008
16. Penson MG, Fricker FJ, Thompson JR, Harker K, Williams BJ, Kahler DA, Schowengerdt KO: Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 20: 611-618, 2001
17. Krmar RT, Ferraris JR, Ramirez JA, Sorroche P, Legal S, Cayssials A: Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol 17: 540-543, 2002
18. Argent E, Kainer G, Aitken M, Rosenberg AR, Mackie FE: Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 7: 38-42, 2003
19. Siirtola A, Virtanen SM, Ala-Houhala M, Koivisto AM, Solakivi T, Lehtimäki T, Holmberg C, Antikainen M, Salo MK: Diet does not explain the high prevalence of dyslipidaemia in paediatric renal transplant recipients. Pediatr Nephrol 23: 297-305, 2008
20. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A: Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 40: 521-527, 2008
21. Mathis AS, Davé N, Knipp GT, Friedman GS: Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61: 565-585, 2004
22. Hohage H, Arlt M, Brückner D, Dietl KH, Zidek W, Spieker C: Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. Clin Transplant 11: 225-230, 1997
23. Brattström C, Wilczek HE, Tydén G, Böttiger Y, Säwe J, Groth CG: Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 30: 3950-3951, 1998 (Pubitemid 29013117)
24. Legendre C, Campistol JM, Squifflet JP, Burke JT: Sirolimus European Renal Transplant Study Group: Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation. Transplant Proc 35: S151-S153, 2003
25. Wlodarczyk Z, Vitko S, Salmela K, Czajkowski Z, Margreiter R; TERRA Study Group: Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. Transplant Proc 37: 1871-1873, 2005
26. Johnstone LM, Jones CL, Grigg LE, Wilkinson JL, Walker RG, Powell HR: Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int 50: 998-1006, 1996
27. Parekh RS, Carroll CE, Wolfe RA, Port FK: Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141: 191-197, 2002
28. Fazelzadeh A, Mehdizadeh AR, Ostovan MA, Raiss-Jalali GA: Predictors of cardiovascular events and associated mortality of kidney transplant recipients. Transplant Proc 38: 509-511, 2006
29. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158-165, 1996
30. Hirsch LJ, Mazzone T: Dexamethasone modulates lipoprotein metabolism in cultured human monocyte-derived macrophages. Stimulation of scavenger receptor activity. J Clin Invest 77: 485-490, 1986
31. Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 19: 625-637, 1981
32. Imamura R, Ichimaru N, Moriyama T, Shi Y, Namba Y, Nonomura N, Matsumiya K, Toki K, Takahara S, Okuyama A: Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus. Clin Transplant 19: 616-621, 2005
33. Lisik W, Schoenberg L, Lasky RE, Kahan BD: Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen. Transplant Proc 39: 3086-3092, 2007
34. Moulin P, Appel GB, Ginsberg HN, Tall AR: Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: Role in dyslipidemia. J Lipid Res 33: 1817-1822, 1992
35. Salazar A, Mana J, Pinto X, Argimon JM, Hurtado I, Pujol R: Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Clin Chim Acta 320: 59-64, 2002
36. Lemieux I, Houde I, Pascot A, Lachance JG, Noël R, Radeau T, Després JP, Bergeron J: Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 62: 1839-1847, 2002
37. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714, 1977
38. Blumenthal RS: Statins: Effective antiatherosclerotic therapy. Am Heart 139: 577-583, 2000
39. Barter PJ, Brabdruo-Wogensen G, Palmer MK, Nicholls SJ: Effect of statins on HDL: A complex process unrelated to changes in LDL: Analysis of the VOYAGER database. J Lipid Res 51: 1546-1553, 2010
40. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505-1515, 2004